CS1 Antibody (E-7): sc-390840

CS1 Antibody (E-7) is a mouse monoclonal IgG1 antibody that detects CS1 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). CS1, also known as novel Ly9, SLAMF7, 19A24, or CRACC, is a homophilic cell surface receptor belonging to the signaling lymphocytic activation molecule (SLAM) family, predominantly expressed on natural killer (NK) cells, T cells, and activated B cells. Anti-CS1 antibody (E-7) recognizes a protein that plays a crucial role in immune responses, particularly in the activation of NK cells, which are essential for the body′s defense against tumors and virally infected cells. CS1′s cytoplasmic domain contains immunoreceptor tyrosine-based switch motifs, facilitating interaction with EAT-2, a protein that induces phosphorylation of CS1 upon ligand binding. This phosphorylation activates downstream cytotoxicity effectors, including phospholipase C gamma and phosphoinositide 3-kinase, thereby enhancing NK cell′s ability to eliminate target cells. While EAT-2 promotes CS1 activation in humans, EAT-2 has an inhibitory effect on NK cell activation in mice, highlighting the complexity of immune regulation mediated by CS1. CS1 (E-7) antibody serves as an invaluable tool for researchers studying immune cell signaling and the intricate mechanisms of immune responses across different species.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CS1 Antibody (E-7) References:

1. Regulation of CS1 fibronectin expression and function by IL-1 in endothelial cells.  |  Boyle, DL., et al. 2000. Cell Immunol. 200: 1-7. PMID: 10716877
2. CS1, a novel member of the CD2 family, is homophilic and regulates NK cell function.  |  Kumaresan, PR., et al. 2002. Mol Immunol. 39: 1-8. PMID: 12213321
3. Molecular and functional characterization of a CS1 (CRACC) splice variant expressed in human NK cells that does not contain immunoreceptor tyrosine-based switch motifs.  |  Lee, JK., et al. 2004. Eur J Immunol. 34: 2791-9. PMID: 15368295
4. CS1-directed monoclonal antibody therapy for multiple myeloma.  |  Benson, DM. and Byrd, JC. 2012. J Clin Oncol. 30: 2013-5. PMID: 22547601
5. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma.  |  Chu, J., et al. 2014. Leukemia. 28: 917-27. PMID: 24067492
6. The alternatively spliced fibronectin CS1 isoform regulates IL-17A levels and mechanical allodynia after peripheral nerve injury.  |  Liu, H., et al. 2015. J Neuroinflammation. 12: 158. PMID: 26337825
7. Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma.  |  Wang, X., et al. 2018. Clin Cancer Res. 24: 106-119. PMID: 29061640
8. The small molecule CS1 inhibits mitosis and sister chromatid resolution in HeLa cells.  |  Wu, X., et al. 2018. Biochim Biophys Acta Gen Subj. 1862: 1134-1147. PMID: 29410075
9. CS1, a controlled-release formulation of valproic acid, for the treatment of patients with pulmonary arterial hypertension: Rationale and design of a Phase 2 clinical trial.  |  Benza, RL., et al. 2024. Pulm Circ. 14: e12323. PMID: 38174159

The preferred CS1 antibody is CS1 Antibody (162.1): sc-53577.